MolGraph
CompoundsDocumentationComplianceAbout
MolGraph

Research chemical sourcing and molecular building block RFQ workflows.

MolGraph is operated by Tessorix Inc.

support@molgraph.com

Products are intended for laboratory research use only and are not for human or veterinary use.

Compounds

  • Compound catalog
  • CAS Search

Company

  • About
  • Contact

Documentation

  • Quality Documentation
  • SDS Disclaimer

Compliance

  • Compliance

Legal

  • Terms
  • Privacy

Copyright © 2026 MolGraph. All Rights Reserved.

Home/Compounds/CAS 1609392-27-9
Formula C20H22N8O3MW 425.5Research-use catalog entryCOA/SDS by request

Deucravacitinib

CAS Number: 1609392-27-9

Sourcing & RFQ

Submit an RFQ to review pricing, availability, lead time, pack size, purity, COA, and supplier SDS for this catalog entry.

Available options

Available Options

Package
1 g
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
1 mg
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
10 g
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
10 mg
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
25 g
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
250 mg
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
5 g
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
5 mg
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required

Shipping review is required before pricing or stock can be confirmed publicly. Shipping, duties, and documentation fees are confirmed before order acceptance.

Loading RDKit molecule structure...
InChIKey: BZZKEPGENYLQSC-FIBGUPNXSA-NC20H22N8O3 | MW 425.5

Chemical Absolute Identifiers

CAS Number

1609392-27-9

PubChem CID

134821691

Molecular Formula

C20H22N8O3

Molecular Weight

425.5 g/mol

Exact Mass

425.200317

InChIKey

BZZKEPGENYLQSC-FIBGUPNXSA-N

IUPAC Name

6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide

SMILES String

[2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4

Physical Properties

No physical property values available.

Properties are provided as catalog reference data and may be confirmed through supplier documentation when required.

Catalog Facts

Structural features

Deucravacitinib (CAS 1609392-27-9) is listed in the Life Science portfolio, with molecular formula C20H22N8O3 and molecular weight 425. 50 g/mol.

Sourcing context

Catalog reference for RFQ preparation, supplier confirmation, and research chemical sourcing review.

Research use context

Intended for life-science research and analytical workflows; structure-derived tags include nitrogen-containing heterocycle.

Documentation needs

COA/SDS status, availability, lead time, pack size, and shipment documentation can be confirmed during quotation.

Applications & Classification

Analytical ScienceLife Science ResearchResearch intermediateCustom synthesis building blockResearch chemical sourcingCustom synthesis and catalog availability reviewCOA, SDS, pricing, and fulfillment workflow
Biological target reference

ChEMBL reports experimental activity evidence for: Non-receptor tyrosine-protein kinase TYK2 (Homo sapiens) — 32 assays; Tyrosine-protein kinase JAK1 (Homo sapiens) — 16 assays; Tyrosine-protein kinase JAK3 (Homo sapiens) — 6 assays; JAK1/TYK2 (Homo sapiens) — 2 assays; Tyrosine-protein kinase JAK2 (Homo sapiens) — 11 assays. These records describe research assays and do not establish therapeutic efficacy or clinical use.

Non-receptor tyrosine-protein kinase TYK2

Homo sapiens · SINGLE PROTEIN · 32 qualifying assays · 16 documents · best pChEMBL 10.7

Experimental evidence source: ChEMBL

Tyrosine-protein kinase JAK1

Homo sapiens · SINGLE PROTEIN · 16 qualifying assays · 6 documents · best pChEMBL 9.64

Experimental evidence source: ChEMBL

Tyrosine-protein kinase JAK3

Homo sapiens · SINGLE PROTEIN · 6 qualifying assays · 4 documents · best pChEMBL 8.52

Experimental evidence source: ChEMBL

JAK1/TYK2

Homo sapiens · PROTEIN COMPLEX · 2 qualifying assays · 2 documents · best pChEMBL 8.3

Experimental evidence source: ChEMBL

Tyrosine-protein kinase JAK2

Homo sapiens · SINGLE PROTEIN · 11 qualifying assays · 5 documents · best pChEMBL 8

Experimental evidence source: ChEMBL

Safety & Handling

Safety and handling reference content is available through documentation requests.

For supplier-issued SDS, request documentation before handling, storage, shipment, or procurement decisions.

Preliminary Safety Reference

For supplier-issued SDS or COA, submit a documentation request.

Safety Reference / SDS Request

Names & Synonyms / External Identifiers

Chemical Name

Deucravacitinib

Names & Synonyms

SotyktuTyk2-IN-4Deucravacitinib [USAN]6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamideDeucravacitinib (BMS-986165)
Show all synonyms
6-[(Cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)-3-pyridazinecarboxamideTyk2-IN-4(BMS986165)bms 986165Sotyktu (TN)Deucravacitinib (JAN/USAN)DEUCRAVACITINIB [INN]DEUCRAVACITINIB [JAN]DEUCRAVACITINIB [WHO-DD]Deucravacitinib(BMS986165)?s8879WHO 11342compound 11 [PMID: 31318208}(BMS-986165)6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide
External Identifiers
EC NUMBER: 870-304-3DSSTOX SUBSTANCE ID: DTXSID701358473CHEMBL ID: CHEMBL4435170UNII: N0A21N6RAUDRUGBANK ID: DB16650KEGG ID: D11817NCI THESAURUS CODE: C174730PHARMGKB ID: PA166432981RXCUI: 2612087WIKIDATA ID: Q113940477
Literature & Patent References
DOI 10.1016/j.bmc.2025.118067An overview of small-molecule agents for the treatment of psoriasis.DOI 10.1021/acs.jmedchem.5c00027Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model.PMID 39832444An overview of small-molecule agents for the treatment of psoriasis.PMID 40116635Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model.DOI 10.1016/j.bmc.2024.117932Design of a potent and selective dual JAK1/TYK2 inhibitor.DOI 10.1016/j.ejmech.2024.116364The role of the methoxy group in approved drugs.DOI 10.1016/j.ejmech.2024.116759A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect.DOI 10.1021/acs.jmedchem.4c00769Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.

Documentation & Compliance Facts

Compliance Facts

Shipment review: Required

Documentation available by request

Certificate of Analysis (COA): By request

Supplier Safety Data Sheet (SDS): By request

Purity and pack size confirmation: By request

Availability and lead time review: Confirmed by RFQ

Shipment documentation review: By request

For supplier-issued documentation by request, use the RFQ actions on this page.Review preliminary safety reference

What happens after RFQ

  1. 1We review the CAS identity, quantity, and documentation request.
  2. 2We check sourcing options, supplier availability, COA/SDS, purity, pack size, and lead time.
  3. 3We review destination and shipment documentation needs when applicable.
  4. 4We follow up with a quotation or clarification request.

Text Reference Cues

Show non-linked catalog cues

Non-public related references

3-Pyridanzinecarboxamide,4,6-dichloro-N-(methyl-d3)CAS 1609393-89-6
Dasatinib-d8CAS 1132093-70-9
Imatinib D4CAS 1134803-16-9
DonafenibCAS 1130115-44-4
Regorafenib-d3CAS 1255386-16-3

Non-public references are shown as text only and do not imply equivalence, availability, or shared use.

Catalog navigation

Related Catalog Entries

Other public CAS pages in this catalog. These links support navigation across additional intermediates and do not imply equivalence, availability, or shared use.

CAS 1310726-60-3UpadacitinibCAS 1187594-09-7BaricitinibCAS 649735-46-6BrivanibCAS 571190-30-2PalbociclibCAS 1002310-00-0Tert-butyl 1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethylcarbamateCAS 1005174-17-3(E)-3-(2-Propyl-6-(trifluoromethyl)pyridin-3-yl)acrylic acidCAS 1018125-49-92-(3-Cyclopropyl-6-ethyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-1-yl)acetic acidCAS 1018128-07-8Isopropyl 4-chloro-2-methylquinoline-6-carboxylateCAS 1018142-22-76-cyclopropyl-1-(2,2-difluoroethyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acidCAS 1018144-00-72-(3-Cyclopropyl-6-isopropyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-1-yl)acetic acid

RFQ questions for CAS 1609392-27-9

What are the key identifiers for Deucravacitinib (CAS 1609392-27-9)?

Deucravacitinib is identified by CAS 1609392-27-9, with molecular formula C20H22N8O3, molecular weight 425.5, InChIKey BZZKEPGENYLQSC-FIBGUPNXSA-N.

Does CAS 1609392-27-9 have reported biological target evidence?

ChEMBL contains qualifying experimental assay evidence associated with Non-receptor tyrosine-protein kinase TYK2, Tyrosine-protein kinase JAK1, Tyrosine-protein kinase JAK3, JAK1/TYK2, Tyrosine-protein kinase JAK2. These records do not establish therapeutic efficacy or clinical use.

Can I request a COA for CAS 1609392-27-9?

Yes. Submit an RFQ and specify COA requirements. Lot-specific COA depends on supplier confirmation.

Can I request supplier SDS for Deucravacitinib?

Yes. Supplier SDS can be requested through the RFQ workflow before handling, storage, shipment, or procurement decisions.

Is CAS 1609392-27-9 available for quotation?

Availability, pack size, lead time, and pricing are confirmed through RFQ.

Can MolGraph support bulk sourcing or custom synthesis review?

Submit the CAS number, quantity, purity requirement, and destination country for sourcing review.